Your browser doesn't support javascript.
loading
Quality of Life and Costs Within Decongestive Lymphatic Therapy in Patients with Leg Lymphedema: A Multicountry, Open-Label, Prospective Study.
Franks, Peter J; Quéré, Isabelle; Keeley, Vaughan; Tilley, Andrea; Liebl, Max; Murray, Susie; Burian, Ewa A; Moffatt, Christine J.
Afiliação
  • Franks PJ; Centre for Research and Implementation of Clinical Practice, London, United Kingdom.
  • Quéré I; National Reference Centre for Rare and Vascular Diseases, Chu-Montpellier, France.
  • Keeley V; Department of Vascular Medicine, UMR IDESP, Université de Montpellier, Chu-Montpellier, France.
  • Tilley A; Lymphoedema Department, University Hospitals of Derby and Burton NHS Trust, Derby, United Kingdom.
  • Liebl M; School of Medicine, University of Nottingham, Nottingham, United Kingdom.
  • Murray S; Archstone Physiotherapy and Wellness Centre, St. John, Canada.
  • Burian EA; Department of Physical Medicine & Rehabilitation, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Moffatt CJ; Centre for Research and Implementation of Clinical Practice, London, United Kingdom.
Lymphat Res Biol ; 19(5): 423-430, 2021 10.
Article em En | MEDLINE | ID: mdl-34582725
ABSTRACT

Background:

Little is known of the impact in terms of health-related quality of life (HRQoL) and cost-effectiveness with decongestive therapy.

Objectives:

To examine changes in limb volume, quality of life (QoL), and treatment cost of methods of decongestive lymphatic therapy (DLT).

Methods:

Patients with chronic edema/lymphedema of the leg were invited to participate in a study of DLT in four countries (United Kingdom, France, Germany, and Canada). In each country two sites were selected. One site used their standard method of DLT in their service, including compression with multilayer bandaging with inelastic material. The other site used a system that included 3M™ Coban 2™ as the bandage treatment alongside other standard components of DLT. Patients were followed for either 2 or 4 weeks depending on the local protocols. At entry, at 2 weeks, and at 4 weeks, patients were assessed by using a health index (EQ-5D), a disease-specific HRQoL tool (LYMQOL) and resource usage was recorded over the treatment period.

Results:

Of the 165 patients with cost data, 90 were treated with Coban 2 and 75 with standard care compression bandaging. There was good evidence of an improvement in EQ-5D of 0.077 (p < 0.001) in all patients. LYMQOL showed significant improvements (p < 0.001) with lower scores. There were no major differences between the two arms of the study with respect to HRQoL. The number of treatment episodes was higher in those treated with standard care (8.15 vs. 6.37), but the overall treatment cost was higher with Coban 2 (£890.7) compared with standard care (£723.0).

Conclusion:

QoL improved in the standard care and Coban 2 group bandages, and there was no demonstrable difference between the care systems. Further work is required to examine the role of the individual parts of DLT that provide the greatest benefit to patients and the health systems that support them.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Linfedema Tipo de estudo: Diagnostic_studies / Guideline / Health_economic_evaluation / Observational_studies Limite: Humans Idioma: En Revista: Lymphat Res Biol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Qualidade de Vida / Linfedema Tipo de estudo: Diagnostic_studies / Guideline / Health_economic_evaluation / Observational_studies Limite: Humans Idioma: En Revista: Lymphat Res Biol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido